Cooperative Agreement UG3CA309489
Award Date 4/1/26
Completion Date 2/29/28
Dollars Obligated $597K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Portland, OR 97239, USA
Similar Awards
- Federal Grant Award Summary Oregon Health & Science University received a $356,850 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2031. The award supports research to develop and evaluate improved cancer treatment methods through the discovery, development, and clinical testing of novel therapeutic approaches. Specifically, the research targets Y-Box Binding Protein 1 (YB-1)...
- Federal Grant Award Summary Oregon Health & Science University received a $625,179 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on March 26, 2026, with completion targeted for February 28, 2031. The award funds research aimed at developing direct and indirect targeting strategies of the MCL1 (myeloid cell leukemia-1) protein to improve therapeutic outcomes for osteosarcoma patients with lung metastasis. The...
- Federal Project Grant Award Summary Oregon Health & Science University received a $2.49 million Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on August 15, 2025, with a completion date of July 31, 2029. The award supports development and validation of fluorescence-guided surgery (FGS) technology to enable real-time nerve visualization during colorectal cancer surgical procedures. The project addresses a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Oregon Health & Science University a $2.27 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, with completion targeted for August 31, 2029. This award supports fundamental research investigating androgen receptor (AR) signaling in conventional dendritic cells (CDCs) and its role in sex-based differences in anti-tumor immune function, particularly in melanoma....
- Federal Project Grant Award Summary The National Cancer Institute awarded Oregon Health & Science University (OHSU) a Project Grant totaling $521,002 under the Cancer Biology Research program (CFDA 93.396) on March 26, 2026, with a completion date of February 28, 2031. This award funds the development and application of a microphysiological bone metastasis-on-a-chip platform designed to advance understanding of prostate cancer metastasis to bone tissue. The research deliverables include an...
- Federal Cooperative Agreement Award Summary The Oregon Health Authority received a $1,283,254 cooperative agreement from the Centers for Disease Control and Prevention (CDC) National Center for Chronic Disease Prevention and Health Promotion under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800). The award, effective August 30, 2025, through August 29, 2030, funds Oregon's efforts to establish and enhance robust colorectal cancer (CRC) screening programs...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $109,076 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective January 16, 2026, with an ultimate completion date of July 15, 2029. The grant supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. OHSU will conduct research investigating the...
- Federal Cooperative Agreement Award Summary Awarded by the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), MedStar Health Research Institute Inc. received $2,677,863 on July 25, 2025, to develop and test implementation strategies for delivering practical geriatric assessment in community oncology settings. The project addresses a critical gap in cancer care for older adults, who will comprise 75% of the 22.2 million projected U.S. cancer...
- Federal Project Grant Summary The National Cancer Institute awarded a $649,293 Project Grant to Ochin, Inc. on September 23, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a longitudinal, multi-level study examining healthcare utilization and outcomes across the cancer care continuum with a focus on social risk factors affecting Latino patients. The research utilizes an electronic health record (EHR)-based dataset from a community health center network...
- The Project Grant award of $637,596.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop and test a video-based intervention to reduce defensive cancer information avoidance and increase the reach of colorectal cancer screening messaging. The intervention is designed to increase self-efficacy and positive affect among those who typically avoid colorectal cancer information, with the goal of improving screening rates. The project includes a...